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INTRODUCTION
Human Immunodeficiency Virus-1 (HIV-
1) presents profound challenges to vaccine
developers. Potential hurdles of relevance
to the design of an effective HIV-1 vac-
cine based on humoral immunity include:
(1) the exceptional rate of mutation of the
viral genome due to an error-prone poly-
merase (i.e., reverse transcriptase) (1), (2)
a relatively high rate of genomic recom-
bination (2, 3), (3) both within-host and
between-host evolution (4), (4) extensive
glycosylation of the chief antigenic target
(gp120) recognized by potentially protec-
tive antibodies (5, 6), (5) immunodomi-
nance of regions of the envelope glycopro-
tein that display a high degree of primary
structure diversity (7) favoring the gen-
eration of neutralizing antibodies of nar-
row breadth, (6) a relatively low density of
antigen spikes on the virion surface (8, 9)
thereby minimizing multivalent antibody
binding and perhaps raising the threshold
affinity required for potent neutralization
by at least some antibodies, (7) the ability
of HIV to infect CD4+ T cells and other
cells critical to functioning of the immune
system, and deplete the numbers of these
cells, and (8) perhaps most insidious, acti-
vation of CD4+ T cells, which is necessary
for the generation of potent broadly neu-
tralizing antibodies in response to immu-
nization may simultaneously increase the
number of cells susceptible to infection by
HIV (10, 11).
The scale of the antigenic diversity char-
acterizing the HIV-1 envelope molecules,
which are the primary targets of antibody-
mediated immunity, is truly daunting.
According to Korber et al. (1), the HIV-1
viral genomes in one infected individual
encompass the same approximate extent
of nucleotide sequence diversity that is
exhibited by the worldwide population of
influenza A viral genomes over the course
of a year.
While most HIV transmission events
appear to trace back to a single virus, up to
a quarter of infections may involve infec-
tion by two to five viruses (12). So, even
if vaccine immunization elicits a robust
antibody response, the probability that the
antibodies circulating in the blood of a vac-
cinated individual will effectively neutral-
ize or otherwise mediate immunity against
all of the viruses mediating infection will
be greatest if those antibodies are broadly
neutralizing. In addition, due to rapid
within-host evolution, substantially differ-
ent viruses may be infecting different indi-
viduals in a large population. Therefore,
antibodies generated by vaccination will
need to be broadly neutralizing to achieve
high levels of vaccine efficacy.
UNIQUE FEATURES OF BROADLY
NEUTRALIZING ANTIBODIES FOR HIV-1
Investigators interested in HIV-1 vaccines
based on humoral immunity have estab-
lished that most neutralizing antibodies in
most patients neutralize a limited range
of strains, primarily those to which the
individual patient was exposed or closely
related strains. In contrast, only about
25–30% of patients synthesize potent and
broadly neutralizing antibodies (pbnAb)
and typically only after 2–4 years follow-
ing the initiation of infection. This time
interval for the development of protective
antibodies is exceptionally long.
The extent of somatic hypermutation
focused on the rearranged immunoglobu-
lin (Ig) genes encoding the heavy and light
chain variable domains and that has been
associated with broad neutralizing activ-
ity against HIV-1 is also extraordinary. Ig
genes encoding typical anti-pathogen anti-
bodies from a mature immune response
may exhibit on the order of 15–20 muta-
tions in the gene segments encoding the
heavy chain variable domain. In con-
trast, many pbnAb for HIV-1 have 40–100
somatic mutations in the genes encod-
ing the heavy chain variable domain. It
seems plausible to infer that a truly excep-
tional extent of Ig gene evolution is con-
tributory to and possibly essential for
the generation of at least some pbnAb.
This inference is supported by the recent
findings that many pbnAb contain many
heavy chain V domain-encoding mutations
in framework regions and these muta-
tions, at both contact and non-contact
positions, are necessary for both high
potency and great breadth of neutral-
ization activity (13). Although, the high
number of variable domain mutations
in pbnAb may also reflect in part the
rapid pace of within-host HIV evolution,
this possibility does not obviously account
for the typical and rather extended time
frame observed for the development of
pbnAb.
In either case, it will also be impor-
tant to study the critical role of follic-
ular helper CD4+ cells (14) in driving
proliferation as well as somatic hypermu-
tation and affinity maturation in germi-
nal center B cells. Another useful focus
for future investigation is based on the
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recent insights regarding the neutralizing
activities of glycan-specific Ab (15).
Thus, it is fair to question whether the
standard approach to clinical vaccination
of administering the same immunogen sev-
eral times is likely to be effective in the
case of HIV-1. A number of major lab-
oratories investigating this problem have
already begun fashioning novel approaches
in which the ultimate overall goal is likely
to be immunization with a series of related
but distinguishable HIV-1-derived enve-
lope molecules that guide the evolution-
ary trajectory for the genes encoding the
variable (V) domains of the correspond-
ing neutralizing antibodies (16). Such a
scheme would appear to recapitulate to
some extent the in vivo process that occurs
for B cells in infected patients. The logistics
of vaccine delivery entailed by this sort of
immunization scheme may be more chal-
lenging than for any previously successful
clinical vaccine.
A crucial feature of this approach of
guiding B cell evolution to the produc-
tion of pbnAb reflects the troubling fact
that the epitope recognized by a protec-
tive Ab at the end of the process may not
be bound by the B cell receptors (BCR) of
the germline B cells from which such anti-
bodies will ultimately be derived by clonal
evolution (16). Therefore, vaccine develop-
ers have begun working to identify antigens
suitable for the activation of the B cells
expressing germline BCRs that can serve
as the ancestral sequences for pbnAb.
This sort of approach is undoubtedly
made more plausible by recent and impres-
sive advances in structure-guided meth-
ods for designing vaccine immunogens
to contain specific epitopes (16, 17). The
results of Dey et al. and Jardine et al. sug-
gest the potential of these new techniques
for eliciting antibody responses of desired
specificity for the HIV-1 envelope protein.
REMAINING QUESTIONS REGARDING
IMMUNITY ELICITED BY
VACCINE-GUIDED B CELL EVOLUTION
Nevertheless, it remains to be determined:
(1) if identification of monoclonal pbnAb
can lead to designed vaccine immuno-
gens that reliably elicit protective poly-
clonal serum or mucosal antibodies, (2)
how many sequential immunogens will
be required to reliably guide the evolu-
tionary trajectory to pbnAb in the great
majority of vaccine recipients, (3) how
many total immunizations will be needed,
(4) what intervals between immunizations
would achieve the optimal balance between
immunogenicity and a timeframe for elic-
itation of protective responses compatible
with public health goals, and (5) how much
expense such a scheme, implemented on a
mass scale, will entail.
The preceding strategy is based on the
assumption that the most viable approach
to generating effective immunity to HIV-
1 is to elicit pbnAb by an active humoral
immune response. There is evidence that
non-neutralizing antibodies may be able to
contribute to immunity to the virus (18–
20), but it appears that only a minority
of investigators focusing on HIV vaccines
based on humoral immunity are persuaded
that such immunity can be of sufficient
potency to protect vaccine recipients in the
absence of pbnAb. It is of importance of
determine if elicitation of non-neutralizing
antibodies to HIV-1 antigens is a feasi-
ble path to successful protection in a high
percentage of vaccine recipients.
REGULATING CD4+ T CELLS AS A PATH
TO IMMUNITY TO HIV-1
A counter-intuitive approach to vaccine
development, although not based in elicita-
tion of humoral immunity, merits brief dis-
cussion. Since HIV-1 infects CD4+ T cells
(which are crucial for the sorts of humoral
immune responses we address above), and
susceptibility to HIV-1 is increased after
activation through the T cell receptor, Lu
et al. (10) reasoned that an immunogen
able to diminish responses of CD4+ T
cells might actually reduce susceptibility
of a recipient of that immunogen to HIV
infection. These authors demonstrated that
administration of an oral vaccine con-
sisting of an inactivated simian immun-
odeficiency virus (SIVmac239) plus the
tolerance-inducing commensal bacterium
Lactobacillus plantarum to macaques pro-
tected them from subsequent intrarectal
challenge. CD8+ T cell-depleting antibod-
ies confirmed the necessary role of CD8+
regulatory T cells to this unusual form of
vaccine-mediated immunity to infection.
In the macaque model of SIV infec-
tion described by Lu et al., the beneficial
effect of reduced responsiveness by CD4+
T cells was mediated by CD8+ T cells recog-
nizing antigens presented by non-classical
MHC class I molecules. It will obviously
be of interest to determine if the same cell
type could operate similarly in humans,
assuming the phenomenon is reproducible
across species. Another important question
that merits investigation is whether this
approach to vaccination is effective in elic-
iting protection against infection for virus
entry by other routes. Even if in humans,
a vaccine targeting CD8+ T cells recog-
nizing antigens presented by non-classical
MHC class I molecules were able to provide
protection from HIV infection, it would
not necessarily rule out the possibility of
manipulating standard CD4+ regulatory T
cells to add to any benefit associated with
CD8+ regulatory T cells.
VECTORED IMMUNOPROPHYLAXIS AS
AN APPROACH TO HUMORAL
IMMUNITY
Another approach to generating humoral
immunity to HIV-1 is based not on induc-
tion of active B cell immunity but on
vectored immunoprophylaxis (21, 22), In
this strategy, a viral vector (e.g., adeno-
associated virus, AAV) is used to infect
or otherwise insert genes encoding intact
potent broadly neutralizing antibodies into
host cells ex vivo with subsequent implan-
tation or in vivo. This scheme provides
arguably passive immunity in that there
is no administration of an immunogen
related to HIV and no elicitation of an
immune response involving host B lym-
phocytes, as usually defined. However, the
production of antibodies is active in the
host and no already synthesized antibodies
are directly infused. Early studies in animal
models have demonstrated proof of princi-
ple for using vectored immunoprophylaxis
to confer robust protection to recipient ani-
mals challenged with significant doses of
virulent HIV by clinically relevant routes
(21, 22).
Of course, applying vectored immuno-
prophylaxis on a mass scale as an alterna-
tive to standard vaccination also requires
addressing so far unanswered questions.
Who should receive the treatment and at
what age? Is a single administration of
the vector sufficient for long-lasting anti-
body production and protection? Are peri-
odic administrations of the vector needed
to maintain persistent protective immu-
nity? Could HIV evolve so as to escape
one or even multiple pbnAb generated
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via vectored immunoprophylaxis? If anti-
body produced by the vector produced
undesirable side-effects, how could syn-
thesis be abrogated in a timely manner?
Will the genetic vectors persist in treated
patients for periods and in ways that
cause unwelcome side-effects? Can propo-
nents of vectored immunoprophylaxis pro-
duce data that will assure the FDA that
these safety concerns have been adequately
addressed?
CONCLUSION
Due to a constellation of attributes includ-
ing enormous genomic and antigenic
sequence diversity, rapid evolution, and
immunity-subverting structural features of
key antigens associated with HIV-1, it is one
of the most challenging pathogens vaccine
developers have confronted to date. Tech-
nological advances in cloning Ig genes from
individual human B lymphocytes, gener-
ating human monoclonal antibodies, and
designing immunogens to express one or
a limited number of epitopes have been
extraordinary and rapid. These advances
make plausible a vaccination scheme cen-
tered on the notion of using a series
of related but non-identical immunogens
to guide the process of B cell evolution
through repeated rounds of somatic hyper-
mutation leading to affinity maturation
and acquisition of broadly neutralizing
activity. However, numerous scientific and
logistical challenges remain to be addressed
before such a scheme could be imple-
mented on a public health scale. Therefore,
alternative strategies to generating protec-
tive immunity to HIV-1, such as vectored
immunoprophylaxis or induction of regu-
latory responses intended to reduce acti-
vation of CD4+ T cells, remain worthy of
thorough exploration.
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